WO2023028430A3 - Growth hormone antagonist and anti-cancer composition combination therapy - Google Patents
Growth hormone antagonist and anti-cancer composition combination therapy Download PDFInfo
- Publication number
- WO2023028430A3 WO2023028430A3 PCT/US2022/074968 US2022074968W WO2023028430A3 WO 2023028430 A3 WO2023028430 A3 WO 2023028430A3 US 2022074968 W US2022074968 W US 2022074968W WO 2023028430 A3 WO2023028430 A3 WO 2023028430A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth hormone
- human growth
- cancer
- composition
- combination therapy
- Prior art date
Links
- 229940122853 Growth hormone antagonist Drugs 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 229940124013 Growth hormone receptor antagonist Drugs 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 108010005905 delta-hGHR Proteins 0.000 abstract 3
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 2
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 2
- 239000000854 Human Growth Hormone Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000001574 biopsy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22862200.7A EP4392055A2 (en) | 2021-08-25 | 2022-08-15 | Growth hormone antagonist and anti-cancer composition combination therapy |
CA3230155A CA3230155A1 (en) | 2021-08-25 | 2022-08-15 | Growth hormone antagonist and anti-cancer composition combination therapy |
JP2024512959A JP2024532319A (en) | 2021-08-25 | 2022-08-15 | Combination therapy of growth hormone antagonist and anticancer composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/411,497 US11857602B2 (en) | 2019-06-17 | 2021-08-25 | Growth hormone antagonist and anti-cancer composition combination therapy |
US17/411,497 | 2021-08-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023028430A2 WO2023028430A2 (en) | 2023-03-02 |
WO2023028430A3 true WO2023028430A3 (en) | 2023-04-06 |
Family
ID=85323353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/074968 WO2023028430A2 (en) | 2021-08-25 | 2022-08-15 | Growth hormone antagonist and anti-cancer composition combination therapy |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4392055A2 (en) |
JP (1) | JP2024532319A (en) |
CA (1) | CA3230155A1 (en) |
WO (1) | WO2023028430A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
US20170007711A1 (en) * | 2015-07-07 | 2017-01-12 | Richard S. Brody | Pegylated growth hormone antagonists |
US20190309308A1 (en) * | 2016-12-02 | 2019-10-10 | Ohio University | Method of Treating Cancer and Method of Sensitizing Cancer Cells to the Action of Chemotherapeutic Agents via Growth Hormone Receptor Antagonists or Knock Down |
US20200390863A1 (en) * | 2019-06-17 | 2020-12-17 | Molecular Technologies Laboratories Llc | Therapeutic pegylated growth hormone antagonists |
-
2022
- 2022-08-15 JP JP2024512959A patent/JP2024532319A/en active Pending
- 2022-08-15 EP EP22862200.7A patent/EP4392055A2/en active Pending
- 2022-08-15 CA CA3230155A patent/CA3230155A1/en active Pending
- 2022-08-15 WO PCT/US2022/074968 patent/WO2023028430A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
US20170007711A1 (en) * | 2015-07-07 | 2017-01-12 | Richard S. Brody | Pegylated growth hormone antagonists |
US20190309308A1 (en) * | 2016-12-02 | 2019-10-10 | Ohio University | Method of Treating Cancer and Method of Sensitizing Cancer Cells to the Action of Chemotherapeutic Agents via Growth Hormone Receptor Antagonists or Knock Down |
US20200390863A1 (en) * | 2019-06-17 | 2020-12-17 | Molecular Technologies Laboratories Llc | Therapeutic pegylated growth hormone antagonists |
Also Published As
Publication number | Publication date |
---|---|
EP4392055A2 (en) | 2024-07-03 |
JP2024532319A (en) | 2024-09-05 |
CA3230155A1 (en) | 2023-03-02 |
WO2023028430A2 (en) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mendelsohn et al. | The EGF receptor family as targets for cancer therapy | |
US20210000816A1 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
Parsai et al. | Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases | |
Chan et al. | Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation | |
WO2020037203A3 (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
Li et al. | Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma | |
Zhang et al. | CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer | |
Raben et al. | Targeted therapies for non–small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective | |
WO2012125573A3 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
Zagozdzon et al. | Truncated HER2: implications for HER2-targeted therapeutics | |
Mita et al. | Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st-to 3rd-line metastatic HER2-negative breast cancer (BC) | |
Li et al. | Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor | |
Scotti et al. | Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells | |
Park et al. | Synergistic inhibitory effect of cetuximab and tectochrysin on human colon cancer cell growth via inhibition of EGFR signal | |
Torp et al. | Coexpression of c-erbB 1–4 receptor proteins in human glioblastomas. An immunohistochemical study | |
WO2023028430A3 (en) | Growth hormone antagonist and anti-cancer composition combination therapy | |
Shirai et al. | Molecular targets in squamous cell carcinoma of the head and neck | |
Normanno et al. | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development | |
Singer | Erratum to: Principles and method of action of targeted therapies | |
Nguyen et al. | Growth factor receptors as targets for lung cancer therapy | |
Knobloch et al. | Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab | |
US10357566B2 (en) | HER3 inhibitor for modulating radiosensitivity | |
Tomblyn et al. | Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice | |
Alvarado et al. | Association of ErbB/HER Biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN | |
Mar et al. | Dual HER2 blockade in non-small cell lung cancer Harboring a HER2 mutation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22862200 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3230155 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2024512959 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022862200 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022862200 Country of ref document: EP Effective date: 20240325 |